Immunome
-
Immunome Prices Public Offering of Common Stock
Immunome has successfully priced a public offering, raising approximately $400 million to advance its targeted cancer therapy development. The funds will fuel the advancement of its pipeline, including late-stage drug varegacestat, ROR1 ADC IM-1021, and FAP-targeted radiotherapy IM-3050, as well as early-stage ADC programs. This capital injection signifies strong investor confidence in the company’s innovative oncology approach.
